Practice-entering research
CheckMate 9DW — nivolumab + ipilimumab in advanced HCC
A Study of Nivolumab Plus Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (CheckMate 9DW)
- Phase
- Phase III
- Recruitment
- Completed
- Results maturity
- Primary analysis
- Publication
- Peer-reviewed
- Regulatory approval
- FDA approval — 11 April 2025 (US)
- NCT
- NCT04039607
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-31
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? Dual immunotherapy prolonged survival versus older targeted drugs in advanced liver cancer. US approval exists; access may differ by country.
Why promising? In advanced HCC, nivolumab+ipilimumab prolonged overall survival versus lenvatinib/sorafenib and is FDA-approved in the US.
What is not proven? All Child-Pugh / stages; Türkiye license; head-to-head ranking versus other 1L IO regimens.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
Lancet 2025: median OS 23.7 vs 20.6 mo (HR 0.79); ORR ≈36% vs 13%. FDA 11 Apr 2025 (US). Early KM crossing / immune toxicity matter. Align with HCC Landmark `checkmate-9dw`.
Cancer / population: Liver (HCC) — Önceden sistemik almamış unresectable HCC; Child-Pugh A
Intervention: Nivolumab + ipilimumab
Primary endpoint: OS
Source-verified summary: OS 23,7 vs 20,6 ay (HR 0,79) — HCC Landmark ile hizalı. FDA 11 Nisan 2025 (ABD).
Limitations: HCC IO alanı hızla değişir; eşzamanlı rejimlerle çapraz okuma; Türkiye erişimi ayrı.
Landmark Atlas links
Cross-links are informational only; this module does not award or change gold stars.